In vitro activity of telithromycin (HMR3647), a new ketolide, against clinical isolates of Mycoplasma pneumoniae in Japan.
The in vitro activity of telithromycin (HMR3647), a new ketolide, against Mycoplasma pneumoniae was determined by the broth microdilution test using 41 clinical isolates obtained in Japan, as compared with those of five macrolides (erythromycin, clarithromycin, roxithromycin, azithromycin, and josamycin), minocycline, and levofloxacin. Telithromycin was less potent than azithromycin, but it was more active than four other macrolides, minocycline, and levofloxacin; its MICs at which 50 and 90% of the isolates tested were inhibited were both 0.00097 microg/ml, justifying clinical studies to determine its efficacy for treatment of M. pneumoniae.
Yamaguchi
T
T
Department of Laboratory Medicine, Nagasaki University School of Medicine, Nagasaki 852-8501, Japan. toshi-ngs@umin.ac.jp
Hirakata
Y
Y
Izumikawa
K
K
Miyazaki
Y
Y
Maesaki
S
S
Tomono
K
K
Yamada
Y
Y
Kamihira
S
S
Kohno
S
S
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D006801:Humans; D007564:Japan; D048628:Ketolides; D018942:Macrolides; D008826:Microbial Sensitivity Tests; D009177:Mycoplasma pneumoniae / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D048628:Ketolides; D018942:Macrolides; C106791:telithromycin